Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 13/20 | 0.64 |
| ▸ | HEXB | P07686 | 3/20 | 0.64 |
| ▸ | HOGA1 | Q86XE5 | 5/20 | 0.60 |
| ▸ | HEXA | P06865 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15612356 | 0.99 | OGA (0.63) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15612359 | 0.99 | OGA (0.63) | OGAHEXBHOGA1HEXA | |
| SCHEMBL12819528 | 0.99 | OGA (0.66) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15611196 | 0.98 | OGA (0.64) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15611197 | 0.98 | OGA (0.64) | OGAHEXBHOGA1HEXA | |
| SCHEMBL12819255 | 0.96 | OGA (0.66) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15611609 | 0.95 | OGA (0.64) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15611605 | 0.95 | OGA (0.64) | OGAHEXBHOGA1HEXA | |
| SCHEMBL12965154 | 0.94 | OGA (0.69) | OGAHEXBHOGA1HEXA | |
| Hydrochloric Acid SCHEMBL15611233 | 0.93 | OGA (0.67) | OGAHEXBHOGA1HEXA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718854-B2 | Selective glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-08-01 | — | — | US | claimed |
| EP-2691407-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2017-02-22 | — | — | EP | claimed |
| US-20140088028-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | PHARMARON BEIJING, CO. LTD. (CN) | 2014-03-27 | — | — | US | claimed |
| EP-2691407-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2014-02-05 | — | — | EP | claimed |
| WO-2012129802-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES AS SELECTIVE GLYCOSIDASE INHIBITORS THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-10-04 | — | — | WO | claimed |
| WO-2012129651-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-10-04 | — | — | WO | claimed |
| US-9718854-B2 | Selective glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-08-01 | — | — | US | disclosed |
| US-9718854-B2 | Selective glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-08-01 | — | — | US | disclosed |
| US-9718854-B2 | Selective glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-08-01 | — | — | US | disclosed |
| EP-2691407-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2017-02-22 | — | — | EP | disclosed |
| EP-2691407-B1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2017-02-22 | — | — | EP | disclosed |
| US-20140088028-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | PHARMARON BEIJING, CO. LTD. (CN) | 2014-03-27 | — | — | US | disclosed |
| US-20140088028-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | PHARMARON BEIJING, CO. LTD. (CN) | 2014-03-27 | — | — | US | disclosed |
| US-20140088028-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | PHARMARON BEIJING, CO. LTD. (CN) | 2014-03-27 | — | — | US | disclosed |
| WO-2012129802-A1 | PYRANO[3,2-D]THIAZOL DERIVATIVES AND USES AS SELECTIVE GLYCOSIDASE INHIBITORS THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012129651-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088028-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, GPI | OGA 1/4885HEXB 53/4885HOGA1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.